1. Home
  2. STTK vs SMID Comparison

STTK vs SMID Comparison

Compare STTK & SMID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Shattuck Labs Inc.

STTK

Shattuck Labs Inc.

HOLD

Current Price

$3.35

Market Cap

119.0M

Sector

Health Care

ML Signal

HOLD

Logo Smith-Midland Corporation

SMID

Smith-Midland Corporation

HOLD

Current Price

$35.91

Market Cap

182.7M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
STTK
SMID
Founded
2016
1960
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Building Materials
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
119.0M
182.7M
IPO Year
2020
1995

Fundamental Metrics

Financial Performance
Metric
STTK
SMID
Price
$3.35
$35.91
Analyst Decision
Buy
Analyst Count
5
0
Target Price
$4.00
N/A
AVG Volume (30 Days)
429.0K
8.6K
Earning Date
11-06-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
81.92
EPS
N/A
2.22
Revenue
$1,000,000.00
$88,866,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$15.86
Revenue Growth
N/A
16.37
52 Week Low
$0.69
$25.13
52 Week High
$3.38
$47.64

Technical Indicators

Market Signals
Indicator
STTK
SMID
Relative Strength Index (RSI) 72.56 50.29
Support Level $2.82 $34.53
Resistance Level $3.29 $36.15
Average True Range (ATR) 0.23 1.50
MACD 0.00 0.15
Stochastic Oscillator 93.75 64.26

Price Performance

Historical Comparison
STTK
SMID

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

About SMID Smith-Midland Corporation

Smith-Midland Corp through its subsidiaries invents, develops, manufactures, markets, sells, and installs precast concrete products for primary use in the construction, highway, utilities, and farming industries. The firm's customers are general contractors and federal, state, and local transportation authorities. Its products include Slenderwall, JJhooks, Softsound, Sierra Wall and Easi set. A substantial portion of the company's business is derived from local, state, and federal building projects. The company generates revenues predominantly from the sale, leasing, licensing, shipping, and installation of precast concrete products for the construction, utility, and farming industries.

Share on Social Networks: